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Background: The BioFreedom (BF) biolimus A9 (BA9) coated stent (Biosensors SA, Switzerland) is a new drug-eluting stent (DES) with a 316L 
stainless steel platform which has been modified with a proprietary surface treatment resulting in a selectively micro-structured abluminal surface. 
This technology allows adhesion of a potent antiproliferative agent (BA9) to the stent’s abluminal surface and further controlled release of the drug 
without the use of a polymer or binder. We report the first-in-man angiographic outcomes of the BF DES w/ 2 different formulations: standard dose 
(SD) and low dose (LD). 
Methods: From Sep/08-Jan/09, 75 pts w/ single coronary lesion were prospectively randomized at 4 sites in Germany in a 1:1:1 ratio for 
treatment with: BF-SD (15.6μg/mm) vs. BF-LD (7.8μg/mm) vs. Taxus paclitaxel-eluting stents (PES). Lesion criteria were native vessels 2.25-3.0mm 
in diameter, and length<14mm. 
Results: Baseline characteristics were comparable among the 3 groups; 38% of lesions were located in LAD, and all pts achieved angiographic 
success. QCA data (in-stent meausres) are shown in the Table. At follow-up (FU), there was no in-stent restenosis or aneurysm formation in all groups. 
Conclusions: The novel BF polymer-free BA9-coated stents showed excellent acute results, and efficacy at 4-month FU including significant 
reductions in late lumen loss (a surrogate of neointimal proliferation) with both BF-SD and BF-LD compared to the Taxus PES. Longer-term FU is 
warranted. (ns=non-significant). 
QCA
BF-SD
N=25
BF-LD
N=26
Taxus PES
N=24
P value
(BF-SD vs. Taxus PES)
P value
(BF-LD vs. Taxus PES)
Lesion length, mm 9.4 10.7 10.9 ns ns
Reference diameter, mm 2.7 2.8 2.7 ns ns
MLD, mm 0.7 0.6 0.7 ns ns
% DS 72.8 78.1 75 ns ns
Final MLD, mm 2.5 2.6 2.6 ns ns
Final % DS 6.3 8.7 6.3 ns ns
Final acute gain, mm 1.7 1.8 1.9 ns ns
Follow-up MLD, mm 2.5 2.5 2.2 ns ns
Follow-up % DS 7.6 10.1 18 0.002 0.02
Follow-up late lumen loss, mm 0.08 0.12 0.37 <0.0001 0.002
